AstraZeneca and Takeda have signed a deal to mutually develop and commercialise an experimental therapy for Parkinson’s disease. The companies will work together to advance AZ’ MEDI1341, an antibody to alpha-synuclein, an aggregation-prone protein that contributes to the development of the condition.
Takeda has initiated a clinical trial testing the potential of the world’s first experimental vaccine for norovirus, which is responsible for nearly three quarters of a billion illnesses and 219,000 deaths each year around the globe. The Phase IIb, double-blind, randomised, placebo-controlled study will be assessing the efficacy of the candidate – via intramuscular administration
Takeda Pharmaceuticals have revealed reasonable financial results for the first nine months of their fiscal year, regardless of the major drop in sales of their diabetes drug, Actos. Japan’s largest drugmaker’s net income for the April-December period dropped 13.5% to 138.91 billion (around $1.51 billion), however sales increased by 5.5% to 1.189 trillion yen. Actos